Apple Watch Blood Oxygen Tracker Back in US With Workaround

Apple Inc. is reinstating the blood oxygen tracking feature on its Apple Watch in the US, following its removal in late 2023 due to a patent infringement lawsuit by Masimo Corp. and a US Customs injunction. This restoration, applicable to models sold with the feature previously disabled, stems from a recent US Customs ruling, resolving a key legal and regulatory challenge for the tech giant and restoring a significant health monitoring capability to the device.

Analysis

Apple Inc. is reinstating its blood oxygen tracking feature in the US, a moderately positive development that resolves a significant legal and regulatory headwind. This action follows the feature's removal in late 2023, which resulted from a patent infringement lawsuit by Masimo Corp. and a subsequent US Customs injunction. The reinstatement, sanctioned by a new US Customs ruling, indicates Apple has successfully implemented a workaround, effectively neutralizing a key aspect of Masimo's legal challenge. This outcome represents a clear operational and legal victory for Apple, restoring a critical health monitoring capability to its product line and removing uncertainty for its wearables segment, as reflected by the positive 0.6 sentiment score for AAPL. Conversely, for Masimo Corp., this is a notable setback; its litigation, which initially forced a product modification, has been circumvented, diminishing the leverage of its patent claims and justifying the negative -0.5 sentiment score for MASI.

Key Decisions for Investors

• For investors in Apple, the resolution of the patent dispute removes a key overhang for its wearables division, reinforcing the company's ability to navigate complex legal challenges and protect its product features.
• Investors holding or considering a position in Masimo should recognize this as a material setback in its litigation strategy against Apple, as the workaround diminishes the potential financial upside from its patent enforcement efforts.
• This event underscores the strategic risk for smaller companies engaging in patent litigation against tech giants like Apple, which possess the resources to engineer solutions that mitigate the impact of legal injunctions.